MLLT11 and cancer: As Ras mutations are the initiating genetic events in many cancers, our data demonstrating the loss of ERK activation downstream of Ras suggest the intriguing possibility that targeting AF1q may provide a useful therapeutic strategy in oncogenic Ras-driven cancers [46].